Cidara Therapeutics (CDTX)
(Delayed Data from NSDQ)
$68.71 USD
-2.51 (-3.52%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $68.70 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CDTX 68.71 -2.51(-3.52%)
Will CDTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CDTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CDTX
Are You Looking for a Top Momentum Pick? Why Cidara Therapeutics (CDTX) is a Great Choice
Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know
CDTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cidara Therapeutics (CDTX) Just Flashed Golden Cross Signal: Do You Buy?
Other News for CDTX
Cidara's Flu Drug: A Phase 2 Triumph, A Phase 3 Gauntlet
CDTX makes New 52 Week High on September 19
CDTX makes New 52 Week Closing High on September 18
Is CDTX likely to continue higher? 20 Day Moving Average Support shows up after rising 0.22%
Cidara Therapeutics (CDTX) Unveils Promising Data on Influenza Drug at ISRV Conference